Anti-Obesity Drugs

Long-term treatment with the anti obesity drugs orlistat, sibutramine or rimonabant produces slight weight loss, but all three drugs influence cardiovascular risk profiles in different ways and have different side effects.

High drop out rate with anti obesity drugs
High drop-out rates -- 30% to 40% -- limits the effectiveness of these drugs.

Effectiveness of anti obesity drugs
Patients taking these anti obesity drugs are more likely than those taking placebo to experience a 5% to 10% reduction in weight. In a review of long term studies, compared with placebo, orlistat reduced weight by 2.9 kg, sibutramine by 4.2 kg, and rimonabant by 4.7 kg.

Benefit of orlistat anti obesity drug
Orlistat reduces the incidence of diabetes and improves levels of total and LDL cholesterol, blood pressure, and glycemic control in patients with diabetes but increases rates of gastrointestinal side effects and lowers HDL levels.

Benefit of sibutramine anti obesity drug
Sibutramine lowers HDL and triglyceride levels but raised blood pressure and pulse rate.

Benefit of rimonabant anti obesity drug
Rimonabant improves HDL and triglyceride levels, as well as blood pressure and glycemic control in diabetic patients but increases mood disorders, such as depression or anxiety. Acomplia may increase the risk for suicide.
 

Home weight loss anti obesity pill home